Bausch + Lomb announced positive results from the pivotal Phase 3 studies with Vesneo (latanoprostene bunod) for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Cumulative lifetime outdoor activities may contribute to exfoliation syndrome (XFS).
Visual field loss from glaucoma is in part reversible by behavioral, computer-based, online controlled vision training.
Use of estrogen-only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG).
Referrals associated with nonmedical factors, with large geographic variations.